Candidate: Vaccine targeting SARS-CoV-2
Type: Combination of Sinovac’s chemically inactivated coronavirus vaccine candidate with Dynavax’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant CpG 1018 ™.
Status: Dynavax told analysts and investors May 19 that it expects that one or more of its collaboration partners “will commence a Phase I clinical trial of a potential COVID-19 vaccine as soon as July 2020,” according to a regulatory filing. regulatory filing.
The partners plan to recruit patients for two randomized, double-blinded, and placebo controlled Phase I/II clinical trials: One is a 422-participant study evaluating the safety and immunogenicity of the vaccine in healthy adults aged ≥60 years. (NCT04383574). The other is a 744-participant study assessing the safety and immunogenicity of the vaccine in healthy adults aged 18~59 Years (NCT04352608).
Sinovac announced the start of the latter trial on April 17. A day earlier, Sinovac and Dynavax said they will partner on a vaccine that combines Sinovac’s vaccine candidate targeting SARS-CoV-2 with CpG 1018, the adjuvant used in HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine marketed by Dynavax following FDA approval in 2017.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: